Overview of Слабилен

This foundational section defines Слабилен and its active compound, Sodium Picosulfate, establishing its classification, composition, and general purpose without addressing dosage, specific clinical indications, or safety protocols.

Quick Facts

Property	Description
Active ingredient	Sodium Picosulfate (INN)
Form	Oral solution, tablets, powder for oral solution
Pharmacological class	Contact Laxative (Stimulant Laxative)
Common use	Facilitates bowel movements
Origin	Synthetic Prodrug

Слабилен: Identity, Composition, and Pharmacological Class

The core of Слабилен is the single active substance, Sodium Picosulfate (Picosulfate Sodium), classifying it as a monopreparation. It is a synthetic compound, chemically manufactured, which places the medication within the Contact Laxative group. As an agent intended for symptomatic treatment of constipation, the drug's primary function is to provide direct stimulation to the large intestine. Sodium Picosulfate is utilized for its predictable activity and is a common ingredient in over-the-counter (OTC) products across many markets.

What Type of Laxative is Sodium Picosulfate and How Does It Function?

Sodium Picosulfate functions as a prodrug, an initially inactive substance that requires chemical conversion to become pharmacologically active. This critical activation occurs in the large intestine: colonic bacterial enzymes hydrolyze the compound to form the potent metabolite BHPM (bis-(p-hydroxy-phenyl)-pyridyl-2-methane). This metabolite acts locally by stimulating the mucosa of the colon. Unlike agents that act via physical bulking, the mechanism of Sodium Picosulfate involves modifying bowel wall function directly.

Available Forms and General Therapeutic Purpose

Слабилен is made available for oral administration in common dosage forms, including a measured oral solution and tablets, as well as a powder for oral solution. The availability of the oral solution often makes it a suitable option for patient groups who have difficulty swallowing solid tablets, such as some children or elderly individuals. The overarching, non-specific therapeutic purpose of this product is to enhance the strength and frequency of peristalsis—the synchronized muscular contractions of the large intestine. By promoting this accelerated movement, the medication effectively facilitates and assists in the general evacuation of intestinal contents, often used in a typical scenario of transient, occasional difficulty with bowel movements.

Regulatory References

About the National Institutes of Health

What side effects are possible with Слабилен?

Possible Side Effects and Safety Information

The safety profile for this medicine, which contains Sodium Picosulfate, is documented by official regulatory authorities through classifications of adverse reactions and defined usage restrictions.

Adverse effects are categorized by frequency and the body system affected. Gastrointestinal disorders are the most commonly reported category, including events officially classified as Common (occurring in ge 1/100 to <1/10 patients) such as abdominal pain, abdominal cramps, diarrhoea, nausea, and vomiting. Other documented effects involve Nervous system disorders (e.g., headache and dizziness) and Immune system disorders (e.g., rash and hypersensitivity), which are typically classified as Uncommon.

Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse events listed in regulatory documents involve Metabolism and nutrition disorders. The label notes the potential for Serious Fluid and Electrolyte Abnormalities, including hyponatraemia and hypokalaemia, with associated risks of cardiac arrhythmias and seizures. This spectrum of risk is officially linked to prolonged or excessive use of the medicine.

Official labels define specific restrictions. The medicine is formally Contraindicated in cases of gastrointestinal obstruction, bowel perforation, severe dehydration, and acute inflammatory bowel diseases. Furthermore, special caution is advised for certain patient groups, with the medicine being explicitly Contraindicated in individuals with severe renal impairment (Creatinine clearance <30 mL/minute) due to elevated safety risk.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on overdose for Слабилен (Sodium Picosulfate) is derived exclusively from authoritative government regulatory documents.

Overdose occurs with the ingestion of an excessive amount of the product (acute) or through prolonged, high-dose administration (chronic abuse).

Documented Overdose Manifestations

Classification	Manifestation/Outcome
Acute Effects	Severe diarrhoea, Abdominal cramps/pain
Serious Outcomes	Clinically significant loss of potassium (Hypokalaemia), Dehydration, Fluid and electrolyte abnormalities
Chronic Abuse	Secondary hyperaldosteronism, Renal tubular damage, Chronic abdominal pain

Required Emergency Actions

Immediate medical advice or attention must be sought if an overdose is suspected. Due to the high risk of serious systemic consequences from fluid and electrolyte loss, contact a poison control center or emergency room at once.

Management is officially described as symptomatic and supportive, focusing on the replacement of fluids and the correction of electrolyte imbalances, as no specific antidote is known for this agent. Regulatory guidance emphasizes that the urgency of monitoring and correcting fluid status is particularly important in the elderly and the young (pediatric patients).

Therapeutic Uses of Слабилен

What Слабилен Treats: Main Uses and Benefits

Слабилен's core therapeutic domain is rooted in the action of its active ingredient, sodium picosulfate, which is generally considered a type of stimulant laxative. This class of medicine is commonly used to help with symptoms related to physical discomfort associated with short-term, occasional constipation.

The product is applied in addressing symptoms of increased neurological or muscular activity in the gut, which assists with the movement of content and contributes to easing the overall symptom load. This action is specifically utilized for the management of short-term, occasional constipation.

The primary contexts of use include: support for occasional constipation and use in specific combination preparations for colon cleansing as a preparation for medical procedures like colonoscopy. The goal is to support the patient during difficult episodes by easing distress.

“The treatment supports general well-being during symptomatic phases.”

Quick Fact: Contributes to easing Physical Discomfort

Regulatory References

UK Government/MHRA report on stimulant laxatives

Eligibility and Restrictions for Use

The eligibility for Слабилен (Sodium Picosulfate) is strictly governed by regulatory documentation, establishing specific populations and conditions where use is permitted, restricted, or prohibited.

Populations Allowed and Age Rules

The medicine is generally indicated for adults and children from 10 years of age for the short-term treatment of occasional constipation. For younger children, use below 10 years of age is not recommended for this indication, as safety and efficacy are not established. Use during breastfeeding is considered acceptable since the active metabolite is undetectable in human milk.

Absolute Contraindications

Слабилен must not be used in patients with the following severe conditions, as formally listed in regulatory labels:

Gastrointestinal Obstruction: Including ileus, toxic megacolon, bowel perforation, or acute abdominal surgical conditions like appendicitis.
Severe Symptoms: Severe abdominal pain accompanied by nausea or vomiting.
Dehydration and Allergy: Cases of severe dehydration or known hypersensitivity to Sodium Picosulfate or its excipients.

Conditional Use and Restrictions

Caution is required for certain groups. Use during pregnancy is generally not recommended, especially in the first trimester, and should only occur on professional medical advice. The product is contraindicated in patients with severely reduced renal function (Creatinine Clearance <30 mL/ minute), especially when formulated with magnesium (Source 2.3, 3.7).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Слабилен (Sodium Picosulfate) is defined by its strong laxative effect, which accelerates gastrointestinal transit and significantly impacts the absorption and systemic exposure of co-administered oral medications.

Pharmacodynamic and Systemic Risk Interactions

Co-administration with Diuretics (e.g., Thiazides, loop diuretics) or systemic Corticosteroids is officially documented to increase the risk of severe fluid and electrolyte disturbances (hypokalemia). This electrolyte shift can be clinically significant, as regulatory documents state it increases the risk of seizures or cardiac arrhythmias when combined with Medications that lower the seizure threshold (e.g., TCAs, SSRIs, Antipsychotics, Carbamazepine).

Absorption and Efficacy Interactions

Reduced Exposure: The rapid intestinal emptying caused by this product can lead to the reduced systemic exposure of nearly all concurrently taken oral medicines.
Mandatory Separation: To mitigate this, specific oral medications such as Digoxin, Iron supplements, and certain Antibiotics (e.g., Fluoroquinolones) require mandatory dosing separation of at least 2 hours before and 6 hours after the treatment.
Antibiotics may also reduce the efficacy of Sodium Picosulfate itself by altering the colonic bacteria necessary for its activation.

Non-Medicinal Substance Restrictions

Intake of Alcohol is restricted due to the documented increased risk of dehydration and dizziness. Consumption of Solid Food and Dairy is prohibited during the treatment period to avoid interference with the prescribed therapeutic regimen.

Mechanism of Action

The pharmacological action of Слабилен (Sodium Picosulfate) is mediated by a precise, localized mechanism that utilizes the body’s own microbial environment to produce a dual action in the large intestine.

Prodrug Activation by Colonic Microflora

The administered drug is an inactive prodrug that must first be chemically converted to become active. This conversion occurs exclusively in the colon, where specific bacterial enzymes (Sulfatase 2) hydrolyze the prodrug into its active metabolite, BHPM (bis-(p-hydroxy-phenyl)-pyridyl-2-methane). This dependency on the colonic microflora is a core mechanistic feature, determining the peripheral site of action and the onset timing of the effect.

Dual Modulation of Motility and Fluid Transport

Once activated, the BHPM metabolite exerts a dual influence on the colonic wall. It acts as a stimulant on the Enteric Nervous System, specifically initiating signaling within the myenteric plexus to increase the frequency and force of peristalsis. Concurrently, it modulates the function of epithelial cells, actively inhibiting the absorption of water and sodium ions while promoting their secretion into the lumen. This combined acceleration of muscular contractions and alteration of contents leads to enhanced physiological propulsion and elimination.

Dosage and Administration Information

The administration of Слабилен is governed by its active compound, Sodium Picosulfate, and the specific clinical context, differentiating between occasional use and procedural bowel cleansing. The approved route of administration for all available dosage forms—including tablets, oral solution, and powder—is strictly oral.

General Principles of Use

For occasional short-term use, the adult regimen involves a dose of 5 mg to 10 mg of Sodium Picosulfate taken once daily. A common practice involves starting at the lowest dose and adjusting only as necessary to achieve the desired response. Administration is typically at night or bedtime, which utilizes the compound's 6-to-12-hour latency period to facilitate evacuation the following morning.

A critical procedural constraint is duration: the product is intended for short-term relief, and continuous daily administration should not exceed five days without investigation of the underlying cause.

Administration Contexts

The dosage for pediatric patients (age 10 years and older) involves lower, scaled doses required for younger children. When the product is used in its powder form for bowel cleansing, the administration involves a specific split-dose regimen that mandates the product be reconstituted with cold water immediately before consumption, followed by the consumption of substantial volumes of additional clear liquids.

Recent Clinical Evidence

Research evidence / Overview of studies for Слабилен (Sodium Picosulfate)

Evidence for Short-term, Occasional Constipation

Research has primarily used short-term Randomized Controlled Trials (RCTs) to evaluate Sodium Picosulfate in adults who experience temporary, acute difficulties with bowel movements. These studies tracked outcomes related to systemic or functional imbalance. Researchers monitored key functional measures, including the speed with which a bowel movement occurred, the overall frequency of movements, and changes in consistency.

Studies have described patterns where measurements indicated changes in stool frequency and consistency over brief observation periods, typically lasting only a few days. Findings describe patterns observed in the studies and document how patients reported their experience with outcomes related to physical discomfort during these short-term episodes.

The evidence is limited regarding long-term outcomes for regular use exceeding four weeks, as follow-up durations were restricted in the primary trials. Comparative evidence is also lacking for certain groups, such as studies exploring comparative patterns against non-stimulant laxatives in specific patient subgroups.

Evidence for Use in Medical Procedure Preparation

The research base includes Randomized Controlled Trials (RCTs) and other comparative studies, where Sodium Picosulfate was observed as a component within a comprehensive regimen used for bowel cleansing. Research examined how a complete cleansing regimen, which included this agent, performed in adults preparing for procedures like colonoscopy. Outcomes reflecting daily functioning were monitored, specifically the quality and completeness of the colon cleanse.

Studies report measurements of the overall adequacy of cleansing. However, since the agent is almost always used as part of a combination regimen, there is limited information on the specific contribution or performance of the picosulfate component when studied as a standalone agent for this purpose.

Research Focus on Chronic Constipation

Research has explored the use of Sodium Picosulfate in the context of symptoms associated with functional chronic constipation. This evidence is derived mainly from systematic reviews and regulatory summaries of efficacy trials. Studies monitored patient-reported outcomes describing perceived discomfort and functional measures, such as the reduction in the need for rescue medication.

Studies report how symptoms evolved in the observed populations during the defined time intervals. The evidence base for this condition is less extensive than that for acute use. The research lacks dedicated, long-duration RCTs (e.g., six months or more) to assess the sustained maintenance of the observed patterns over time. As a result, certainty remains low and long-term effects are not fully established regarding sustained, regular use.

Frequently Asked Questions (FAQ)

Common questions about Слабилен (FAQ)

Q: How does Слабилен work differently than other similar products?

The medicine is classified by regulators as a stimulant laxative that acts locally in the colon. Its mechanism is unique because it is an inactive substance (a prodrug) that must be converted by specific bacteria inside the large intestine to become active. This active form then directly stimulates the colon's muscle movement and fluid secretion, setting it apart from physical agents like bulk-forming laxatives.

Q: How long does it typically take to start working after the first dose?

According to the official product information, the medicine has a latency period before the effect starts. For occasional use, the onset of action is typically observed approximately 6 to 12 hours after taking the dose.

Q: Can Слабилен be taken with vitamins or supplements?

The rapid bowel transit caused by this product may lead to reduced absorption of nearly all other concurrently taken oral products. This can include vitamins and dietary supplements. Official documents specify that products like Iron supplements require a mandatory separation period when dosing.

Q: What is the safety classification of Слабилен according to regulators?

For the short-term relief of occasional constipation, the product containing Sodium Picosulfate is generally classified as an Over-the-Counter (OTC) medicine in many regulated markets. This classification is for its use as a common, readily available laxative.

Q: Does Слабилен affect the body's absorption of nutrients?

Studies and official information indicate that chronic or excessive daily use may affect the body's ability to absorb specific nutrients. This potential reduction mainly applies to fat-soluble vitamins (Vitamins A, D, E, and K) and certain minerals, such as calcium.

Q: Are there any age limits for using Слабилен, other than for children?

Official documents establish age limits for children but do not specify an upper age limit for adults. However, official warnings highlight a need for special consideration for patients who have underlying health conditions common in the elderly, such as severe renal impairment or heart disease. This consideration is primarily due to the increased risk of severe fluid and electrolyte imbalances in these populations.

Q: Does Слабилен interact with common heart medications?

Regulatory documents specifically detail interactions with certain heart-related medications. The risk of severe electrolyte imbalance is increased when used with Diuretics or Corticosteroids. This imbalance can increase sensitivity to drugs like cardiac glycosides (e.g., Digoxin) and may raise the risk of developing cardiac arrhythmias.

Q: What is the duration of effect of Слабилен?

The medicine is designed to induce a single, controlled intestinal evacuation. The onset of action is generally documented as occurring approximately 6 to 12 hours after administration. The product's therapeutic effect is generally considered to be complete once the intestinal evacuation has ceased.

Q: Why do some people say Слабилен is habit-forming? / Does the body get used to the effects of Слабилен over time?

Regulatory documents contain warnings against the use of the product for long periods or in excessive amounts. This is because prolonged reliance on stimulant laxatives can lead to the bowel becoming dependent on the medicine to function. This condition of dependence is sometimes referred to as cathartic colon in official warnings.

Q: What should be done if someone misses a dose of Слабилен?

General instructions for missed doses are often omitted for this type of as-needed medicine. If the product is being used as part of a preparation regimen, guidance provided in regulatory documents often recommends consulting a healthcare professional for specific advice. Regulatory guidance typically states that a double dose must not be taken.

Q: What does official guidance say about stopping the use of Слабилен?

Official guidance indicates that the medicine is only for short-term use to treat occasional difficulties. Once regular bowel function has resumed, official documents describe a process where the dosage is reduced and then discontinued once regularity is restored.

Q: Can Слабилен be used by individuals with diabetes?

Regulatory summaries and clinical data list diabetes as a potential risk factor that may require careful consideration. Regulatory information highlights the need for caution, as the product can interact with some diabetes medications.

Q: Are the side effects the same for all forms of Слабилен?

The product's side effect profile is fundamentally tied to its active ingredient, Sodium Picosulfate. Since this ingredient is the same across the tablets, oral solution, and powder, the documented side effects are the same. The exact frequency of these side effects, however, may be influenced by the specific product formulation.

Q: Why is Bisacodyl sometimes compared to the active ingredient in Слабилен?

Bisacodyl is commonly compared to Sodium Picosulfate in regulatory reviews and clinical studies. This is because both agents are classified as stimulant laxatives and are metabolized in the colon into the same final active substance, BHPM, which performs the therapeutic action.

Q: What is the role of the liver in processing Слабилен?

Official pharmacological properties indicate that the product is an inactive prodrug that is activated locally by bacterial enzymes in the colon. Because of this activation mechanism, the main site of action is peripheral, meaning it does not require initial processing by the liver to become effective.

Q: Is it described as safe to use Слабилен after surgery?

The medicine is contraindicated in cases of acute abdominal surgical conditions, such as intestinal obstruction or appendicitis. Official documentation contains warnings regarding the need for special consideration when reviewing its use in patients who have undergone recent gastro-intestinal surgery.

Q: Does Слабилен have any known interaction with herbal teas?

Regulatory documents do not specifically detail interactions with herbal teas. However, Official documentation recommends disclosing the use of all supplements and herbal products to a healthcare professional. This is important due to the risk of reduced absorption of other medicines or potential fluid and electrolyte imbalances.

How should Слабилен be stored and disposed of?

Official Storage and Disposal Requirements

Слабилен (Sodium Picosulfate) must be stored strictly according to the conditions documented in regulatory labeling to maintain its quality and labeled 3-year shelf-life.

The medicine is required to be stored at a temperature not exceeding 25 C. To protect the product integrity, it must be kept protected from light and stored in its original primary packaging.

Safety and Handling

The product must be stored out of the reach of children as a mandatory safety requirement.

For disposal of expired or unused product, official instructions require that it be discarded according to local regulations. Individuals should consult with a pharmacist or local waste management facility for specific guidance on pharmaceutical waste.

Слабилен